ArticleOncoTargets and therapy2026
Prognostic Value of BMI in Patients with Metastatic Cervical Cancer:A Retrospective Study From Turkey.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity has been associated with adverse outcomes in several malignancies; however, the prognostic significance of body mass index (BMI) in metastatic cervical cancer remains unclear because of limited and conflicting evidence. This study aimed to evaluate the impact of BMI on progression-free survival (PFS) and overall survival (OS) in women with metastatic cervical cancer. Methods: A retrospective analysis was conducted on 60 women diagnosed with metastatic cervical cancer between February 2014 and January 2024. Patients were stratified into high (≥25 kg/m Results: Among the cohort, 70% of patients had a BMI ≥25. There were no significant differences between BMI groups in baseline characteristics such as age, histological subtype, or metastatic site. However, patients with a BMI <25 demonstrated significantly better OS (2- and 5-year OS: 55.0% and44.0%) compared to those with a BMI ≥25 (22.2% and 17.8%, p = 0.024). A similar trend was observed for PFS (p = 0.037). In multivariable analysis, high BMI remained independently associated with worse OS (HR=2.55, 95% CI=1.18-5.50, p=0.017) and PFS (HR=1.87, 95% CI=1.01-3.66, p=0.045). Conclusion: Higher BMI is associated with poorer overall survival in patients with metastatic cervical cancer. These findings highlight the importance of nutritional assessment and suggest that BMI may serve as a prognostic marker associated with survival outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.